MedTrace Logo

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

NCT05595460 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-04-13

No results posted yet for this study

Summary

This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.

Conditions

  • SCLC,Extensive Stage

Interventions

DRUG

RYZ101 Dose Level 1

Dose Level 1

DRUG

RYZ101 Dose Level 2

Dose Level 2

DRUG

RYZ101 Dose Level 3

Dose Level 3

DRUG

RYZ101 Dose Level -1

Dose Level -1

DRUG

Atezolizumab

Atezolizumab

DRUG

Carboplatin

Carboplatin

DRUG

Etoposide

Etoposide

Sponsors & Collaborators

  • RayzeBio, Inc.

    lead INDUSTRY

Principal Investigators

  • Petrus De Jong, MD · RayzeBio, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-10
Primary Completion
2027-07-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05595460 on ClinicalTrials.gov